Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

As PennantPark Risk/Reward Balances, D.A. Davidson Downgrades To Neutral

As PennantPark Risk/Reward Balances, D.A. Davidson Downgrades To Neutral

D.A. Davidson downgraded PennantPark Investment Corp. (NASDAQ: PNNT) to Neutral from Buy to reflect recent outperformance of shares, which, according to the analysts, gives a more balanced risk/reward given remaining oil and gas exposures.

"PNNT's year-to-date total return (including dividends) of 30.5 percent compares to an average total return of 9.8 percent for other BDCs in our coverage and 7.4 percent for the S&P 500," wrote D.A. Davidson.

Related Link: JPMorgan Downgrades PennantPark To Neutral

The analysts believe the valuation is appropriate, despite trading at a 84 percent discount to NAV, taking into account the company's remaining exposure to oil and gas investments at 15 percent of cost and 9 percent of fair value.

The company has a 12–18-month price target of $7 on PennantPark shares.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for PNNT

May 2019DowngradesBuyNeutral
Apr 2019Initiates Coverage OnOutperform
Jan 2019DowngradesOverweightNeutral

View More Analyst Ratings for PNNT
View the Latest Analyst Ratings

Posted-In: D.A. Davidson gasAnalyst Color Downgrades Commodities Markets Analyst Ratings Tech


Related Articles (PNNT)

View Comments and Join the Discussion!

Latest Ratings

NANOInitiates Coverage On41.0
PAYCInitiates Coverage On
PCTYInitiates Coverage On
UPWKInitiates Coverage On
NTGRInitiates Coverage On40.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Jack Dorsey Needs To Make A Choice

Can Keytruda Deliver Earnings Growth For Merck?